b RAS G12, G13 or Q61 mut or no RAS mut identified. This is an ASCO Meeting Abstract from the 2026 ASCO Annual Meeting II. This abstract does not include a full text component.

This year’s meeting of the American Society of Clinical Oncology is abuzz with talk of RAS inhibitors, largely driven by Revolution Medicines’ barnburner pancreatic cancer data drop earlier this year.

The Higher Education Commission of Pakistan (HEC) on Monday announced the launch of a “fully online and paperless” degree attestation system to facilitate students. In December last year, the HEC said ...

Ras Al Khaimah’s residential property market recorded AED12.4bn ($3.4bn) in home sales across 6,600 transactions in 2025, underlining continued investor interest in the northern emirate. The ...

After dropping headline-grabbing phase 3 data for its pancreatic cancer candidate daraxonrasib last week, Revolution Medicines is not resting on its laurels. The Bay Area biotech has spent several ...

Abstract: Despite the numerous advantages dams pose a risk if not properly designed or maintained. With the changes in climate there are extreme events going on and increased precipitation is the most ...

Bain Capital agreed to sell its data centers in China to Shenzhen Dongyangguang Industry Co. in a transaction valued at about $4 billion. Shenzhen Dongyangguang, the parent of Shanghai-listed ...

TAS102 in combination with oxaliplatin (TASOX) for refractory metastatic colorectal cancer. Efficacy and safety of glecirasib (JAB-21822) monotherapy and in combination with cetuximab in patients with ...

The NFL Draft is one of the most crucial events in football, where teams sift through a pool of talented prospects to shape the future of their franchise. While traditional scouting methods still hold ...